Naci, Huseyin

Number of items: 144.
Article
  • Papanicolas, Irene, Wouters, Olivier J., Sawaya, Tania, Han, Jihye, Wei, Jinru, Naci, Huseyin (2026). Review times for new drugs and submission delays among the FDA and 4 international regulators, 2014–22. Health Affairs, 45(2), 184-192. https://doi.org/10.1377/hlthaff.2025.00595
  • McGonigle, Rylee, Naci, Huseyin, Siebert, Maximilian, Ouvina, Michelle, Gutierrez-Sacristan, Alba, Wagner, Anita K., Bourgeois, Florence T. (2025). Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: a retrospective cohort study. PLoS Medicine, 22(12). https://doi.org/10.1371/journal.pmed.1004651 picture_as_pdf
  • Naci, Huseyin, Shahzad, Mahnum, Murphy, Peter, Zhang, Yichen, Costa, Rebecca, Ross, Joseph S., Wagner, Anita K. (2025). Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation. BMJ Medicine, 4(1). https://doi.org/10.1136/bmjmed-2025-001934 picture_as_pdf
  • Cherla, Avi, Wagner, Anita K., Wouters, Olivier J., Woloshin, Steven, Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2025). Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines. JAMA, 334(16), 1480 - 1482. https://doi.org/10.1001/jama.2025.13917 picture_as_pdf
  • Zhang, Yichen, Li, Huangqianyu, Chen, Jinyu, Naci, Huseyin, Wagner, Anita K, Shi, Luwen, Guan, Xiaodong (2025). Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study. BMJ Evidence-Based Medicine, https://doi.org/10.1136/bmjebm-2025-113722 picture_as_pdf
  • Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin, Wagner, Anita K., Ross, Joseph S., Guan, Xiaodong (2025). Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology, 26(9), 1252 - 1260. https://doi.org/10.1016/S1470-2045(25)00329-8 picture_as_pdf
  • Gainsbury, Sally, Naci, Huseyin (2025). Improving productivity in the NHS. BMJ, 390, https://doi.org/10.1136/bmj.r1722
  • Cherla, Avi, Woloshin, Steven, Wagner, Anita K., Wouters, Olivier J., Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2025). New cancer drug approvals: less than half of important clinical trial uncertainties reported by the FDA to clinicians, 2019–22. Health Affairs, 44(7), 830 - 838. https://doi.org/10.1377/hlthaff.2024.01134 picture_as_pdf
  • Naci, Huseyin, Murphy, Peter, Woods, Beth, Lomas, James, Wei, Jinru, Papanicolas, Irene (2025). Population health impact of NICE-recommended new drugs – authors' reply. The Lancet, 405(10497), 2277 - 2278. https://doi.org/10.1016/S0140-6736(25)01078-5
  • Cherla, Avi, Naci, Huseyin, Woloshin, Steven, Wagner, Anita Katharina, Ong, Mei-Sing (2025). Communication of uncertainties about recent cancer drugs in large language models. Journal of Clinical Oncology, 43(16_suppl), 11026 - 11026. https://doi.org/10.1200/jco.2025.43.16_suppl.11026
  • Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin, Wagner, Anita Katharina, Ross, Joseph S., Guan, Xiaodong (2025). Strength of evidence supporting cancer drug approvals in China, 2017-2021. Journal of Clinical Oncology, 43(16_suppl). https://doi.org/10.1200/jco.2025.43.16_suppl.tps11188
  • Pollicino, Daniele, Zamzow, Heidi, Shreedhar, Ganga, Galizzi, Matteo M., Naci, Huseyin, Freitag, Patricia (2025). Can social norms promote sustainable food consumption? A systematic review. Social Influence, 20(1). https://doi.org/10.1080/15534510.2025.2497341 picture_as_pdf
  • Naci, Huseyin, Murphy, Peter, Woods, Beth, Lomas, James, Wei, Jinru, Papanicolas, Irene (2025). Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. The Lancet, 405(10472), 50 - 60. https://doi.org/10.1016/S0140-6736(24)02352-3 picture_as_pdf
  • Forrest, Robin, Lagarde, Mylene, Aggarwal, Ajay, Naci, Huseyin (2024). Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. The Lancet Oncology, 25(12), 1635 - 1643. https://doi.org/10.1016/S1470-2045(24)00596-5 picture_as_pdf
  • Shahzad, Mahnum, Naci, Huseyin, Esselen, Katharine M., Dottino, Joseph A., Wagner, Anita K. (2024). Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway. Journal of Pharmaceutical Policy and Practice, 17(1). https://doi.org/10.1080/20523211.2024.2351003 picture_as_pdf
  • Lythgoe, Mark P., Emhardt, Alica Joana, Naci, Huseyin, Krell, Jonathan, Sullivan, Richard, Aggarwal, Ajay (2024). Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis. The Lancet Regional Health - Europe, 46, https://doi.org/10.1016/j.lanepe.2024.101062 picture_as_pdf
  • Soumerai, Stephen B., Koppel, Ross, Naci, Huseyin, Madden, Jeanne M., Fry, Andra, Halbisen, Alyssa, Angeles, Jesenia, Koppel, Jonah, Rubin, Rachelle, Lu, Christine Y. (2024). Intended and unintended outcomes after FDA pediatric antidepressant warnings: a systematic review. Health affairs (Project Hope), 43(10), 1360 - 1369. https://doi.org/10.1377/hlthaff.2023.00263 picture_as_pdf
  • Davis, Courtney, Wagner, Anita K., Mintzes, Barbara, Scowcroft, Henry, Woloshin, Steven, Naci, Huseyin (2024). Patients deserve better information on new drugs. BMJ (Clinical research ed.), 387, https://doi.org/10.1136/bmj-2024-081720
  • Salcher-Konrad, Maximilian, Nguyen, Mary, Savović, Jelena, Higgins, Julian P. T., Naci, Huseyin (2024). Treatment effects in randomized and nonrandomized studies of pharmacological interventions: a meta-analysis. JAMA network open, 7(9). https://doi.org/10.1001/jamanetworkopen.2024.36230 picture_as_pdf
  • Tinelli, Michela, Athanasiou, Antonios, Veroniki, Areti angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Bowden, Sarah, Paraskevaidi, Maria, Lyons, Deirdre, Martin‐hirsch, Pierre & Bennett, Phillip et al (2024). Treatment methods for cervical intraepithelial neoplasia in England: a cost‐effectiveness analysis. BJOG: An International Journal of Obstetrics and Gynaecology, 131(10), 1411 - 1419. https://doi.org/10.1111/1471-0528.17829 picture_as_pdf
  • de Sá, Thiago Hérick, Sudsataya, Daniele, Fry, Andra, Salehi, Nazak, Katiki, Aishwarya, Mcleod, Megan, Rathmell, Greg, Cylus, Jon, Lafortune, Louise & Buffel, Tine et al (2024). The impact of transport, housing, and urban development interventions on older adults' mobility: a systematic review of experimental and quasi-experimental studies. Journal of Transport and Health, 38, https://doi.org/10.1016/j.jth.2024.101859 picture_as_pdf
  • Wouters, Olivier J., Naci, Huseyin, Papanicolas, Irene (2024). Health Technology Assessment in the US—a word of caution—reply. JAMA Internal Medicine, 184(7), 851 - 851. https://doi.org/10.1001/jamainternmed.2024.1461
  • Naci, Huseyin, Zhang, Yichen, Woloshin, Steven, Guan, Xiaodong, Xu, Ziyue, Wagner, Anita K. (2024). Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. The Lancet Oncology, 25(6), 760 - 769. https://doi.org/10.1016/S1470-2045(24)00152-9 picture_as_pdf
  • Wei, Yuxuan, Zhang, Yichen, Xu, Ziyue, Wang, Guoan, Zhou, Yue, Li, Huangqianyu, Shi, Luwen, Naci, Huseyin, Wagner, Anita K., Guan, Xiaodong (2024). Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020. The Lancet Regional Health - Western Pacific, 45, https://doi.org/10.1016/j.lanwpc.2024.101055 picture_as_pdf
  • Swift, Bethan, Taneri, Bahar, Becker, Christian M., Basarir, Hasan, Naci, Huseyin, Missmer, Stacey A., Zondervan, Krina T., Rahmioglu, Nilufer (2024). Prevalence, diagnostic delay and economic burden of endometriosis and its impact on quality of life: results from an Eastern Mediterranean population. European Journal of Public Health, 34(2), 244 - 252. https://doi.org/10.1093/eurpub/ckad216 picture_as_pdf
  • Wouters, Olivier J., Naci, Huseyin, Papanicolas, Irene (2024). Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies. Journal of American Medical Association: Internal Medicine, 184(3), 328 - 330. https://doi.org/10.1001/jamainternmed.2023.7726 picture_as_pdf
  • Zhou, Yue, Naci, Huseyin, Chen, Dingyi, Bai, Lin, Shi, Luwen, Guan, Xiaodong, Wagner, Anita Katharina (2023). Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021. BMJ Global Health, 8(9). https://doi.org/10.1136/bmjgh-2023-012899 picture_as_pdf
  • STRiDE Evidence Review Group (2023). Research evaluating the effectiveness of dementia interventions in low- and middle-income countries: a systematic mapping of 340 randomised controlled trials. International Journal of Geriatric Psychiatry, 38(7). https://doi.org/10.1002/gps.5965 picture_as_pdf
  • Ivama-Brummell, Adriana M., Marciniuk, Fernanda L, Wagner, Anita K., Osorio-de-Castro, Claudia G. S., Vogler, Sabine, Mossialos, Elias, Tavares-de-Andrade, Carla L., Naci, Huseyin (2023). Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis. The Lancet Regional Health - Americas, 22, https://doi.org/10.1016/j.lana.2023.100506 picture_as_pdf
  • Parvanova, Iva, Gentilini, Arianna, Cushing, Jonathan, Naci, Huseyin (2023). Safeguarding NICE from patient groups' conflicts of interest. BMJ, 381, https://doi.org/10.1136/bmj.p1243
  • Forrest, Robin, Naci, Huseyin (2023). Prioritising patients in negotiations over drug pricing. BMJ (Clinical research ed.), 381, https://doi.org/10.1136/bmj.p829
  • Cherla, Avi, Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2023). Faster UK drug approvals by relying on other countries. BMJ (Clinical research ed.), 381, p. 739. https://doi.org/10.1136/bmj.p739
  • Davis, Courtney, Wagner, Anita K., Salcher-Konrad, Maximilian, Scowcroft, Henry, Mintzes, Barbara, Pokorny, Adrian M J, Lew, Jianhui, Naci, Huseyin (2023). Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ, 380, e073711. https://doi.org/10.1136/bmj-2022-073711 picture_as_pdf
  • Shahzad, Mahnum, Naci, Huseyin, Wagner, Anita K. (2023). Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. JAMA, 329(9), 760 - 761. https://doi.org/10.1001/jama.2023.0625
  • Naci, Huseyin, Forrest, Robin, Zhai, Mike, Stofesky, Amanda R., Kesselheim, Aaron S. (2023). Characteristics of prior authorization policies for new drugs in Medicare Part D. JAMA Health Forum, 4(2). https://doi.org/10.1001/jamahealthforum.2022.5610 picture_as_pdf
  • Vokinger, Kerstin N., Naci, Huseyin (2022). Negotiating drug prices in the US - lessons from Europe. JAMA Health Forum, 3(12). https://doi.org/10.1001/jamahealthforum.2022.4801 picture_as_pdf
  • Ostinelli, Edoardo Giuseppe, Efthimiou, Orestis, Naci, Huseyin, Furukawa, Toshi A., Leucht, Stefan, Salanti, Georgia, Wainwright, Laurence, Zangani, Caroline, De Crescenzo, Franco & Smith, Katharine et al (2022). Vitruvian plot: a visualisation tool for multiple outcomes in network meta-analysis. Evidence-Based Mental Health, 25(e1), e65 - e70. https://doi.org/10.1136/ebmental-2022-300457 picture_as_pdf
  • Carl, David L., Laube, Yannic, Serra-Burriel, Miquel, Naci, Huseyin, Ludwig, Wolf Dieter, Vokinger, Kerstin N. (2022). Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland. JAMA network open, 5(12). https://doi.org/10.1001/jamanetworkopen.2022.44670 picture_as_pdf
  • Cherla, Avi, Mossialos, Elias, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Naci, Huseyin (2022). Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. Clinical Pharmacology and Therapeutics, 112(4), 846 - 852. https://doi.org/10.1002/cpt.2679 picture_as_pdf
  • Blankart, Katharina, Naci, Huseyin, Chandra, Amitabh (2022). Availability of new medicines in the US and Germany from 2004 to 2018. JAMA network open, 5(8). https://doi.org/10.1001/jamanetworkopen.2022.29231 picture_as_pdf
  • Zhang, Yichen, Naci, Huseyin, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen, Guan, Xiaodong (2022). Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA network open, 5(8). https://doi.org/10.1001/jamanetworkopen.2022.25973 picture_as_pdf
  • Athanasiou, Antonios, Veroniki, Areti Angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Naci, Huseyin, Bowden, Sarah, Paraskevaidi, Maria, Arbyn, Marc, Lyons, Deirdre & Martin-Hirsch, Pierre et al (2022). Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis. The Lancet Oncology, 23(8), 1097 - 1108. https://doi.org/10.1016/S1470-2045(22)00334-5 picture_as_pdf
  • Costa, Suzete, Romão, Mariana, Mendes, Maria, Horta, Maria Rute, Rodrigues, António Teixeira, Carneiro, António Vaz, Martins, Ana Paula, Mallarini, Erika, Naci, Huseyin, Babar, Zaheer Ud Din (2022). Pharmacy interventions on COVID-19 in Europe: mapping current practices and a scoping review. Research in Social and Administrative Pharmacy, 18(8), 3338 - 3349. https://doi.org/10.1016/j.sapharm.2021.12.003 picture_as_pdf
  • Swift, B., Naci, H., Taneri, B., Becker, C. M., Zondervan, K. T., Rahmioglu, N. (2022). The Cyprus Women’s Health Research (COHERE) initiative: normative data from the SF-36v2 questionnaire for reproductive aged women from the Eastern Mediterranean. Quality of Life Research, 31(7), 2011 - 2022. https://doi.org/10.1007/s11136-022-03100-7 picture_as_pdf
  • Naci, Huseyin, Kyriopoulos, Ilias-Ioannis, Feldman, William B., Hwang, Thomas J., Kesselheim, Aaron S., Chandra, Amitabh (2022). Coverage of new drugs in Medicare Part D. Milbank Quarterly, 100(2), 562 - 588. https://doi.org/10.1111/1468-0009.12565 picture_as_pdf
  • Kapelios, Chris J., Naci, Huseyin, Vardas, Panos E., Mossialos, Elias (2022). Study design, result posting, and publication of late-stage cardiovascular trials. European Heart Journal - Quality of Care and Clinical Outcomes, 8(3), 277 - 288. https://doi.org/10.1093/ehjqcco/qcaa080
  • Vokinger, Kerstin N., Hwang, Thomas J., Carl, David L., Laube, Yannic, Ludwig, Wolf Dieter, Naci, Huseyin, Kesselheim, Aaron S. (2022). Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. The Lancet Oncology, 23(4), 514 - 520. https://doi.org/10.1016/S1470-2045(22)00073-0
  • Bartholomew, Theodore, Naci, Huseyin, Robertson, Emma, Schmidt, Harald (2022). Use of adherence monitoring in drug contracts tied to outcomes: put patients first. BMJ (Clinical research ed.), 376, https://doi.org/10.1136/bmj-2020-062188 picture_as_pdf
  • Fu, Mengyuan, Naci, Huseyin, Booth, Christopher M., Gyawali, Bishal, Cosgrove, Austin, Toh, Sengwee, Xu, Ziyue, Guan, Xiaodong, Ross-Degnan, Dennis, Wagner, Anita K. (2021). Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 181(12), 1596 - 1604. https://doi.org/10.1001/jamainternmed.2021.5983
  • Naci, Huseyin, Guan, Xiaodong, Woloshin, Steven, Xu, Ziyue, Wagner, Anita K. (2021). Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. JAMA Internal Medicine, 181(11), 1521 - 1522. https://doi.org/10.1001/jamainternmed.2021.3505 picture_as_pdf
  • Dawoud, Dalia, Naci, Huseyin, Ciani, Oriana, Bujkiewicz, Sylwia (2021). Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. The BMJ, 374, https://doi.org/10.1136/bmj.n2191 picture_as_pdf
  • Cherla, Avi, Naci, Huseyin, Mossialos, Elias (2021). The coverage in England of US-approved cancer drugs reply: in reply. JAMA Internal Medicine, 181(9), 1263 - 1264. https://doi.org/10.1001/jamainternmed.2021.3339
  • Beirne, Anne Marie, Mitchelmore, Oliver, Palma, Susana, Andiapen, Mervyn, Rathod, Krishnaraj S., Hammond, Victoria, Bellin, Anna, Cooper, Jackie, Wright, Paul & Antoniou, Sotiris et al (2021). NITRATE-CIN Study: Protocol of a Randomized (1:1) Single-Center, UK, Double-Blind Placebo-Controlled Trial Testing the Effect of Inorganic Nitrate on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography for Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 26(4), 303-309. https://doi.org/10.1177/1074248421000520 picture_as_pdf
  • Cherla, Avi, Naci, Huseyin, Kesselheim, Aaron S., Gyawali, Bishal, Mossialos, Elias (2021). Assessment of coverage in England of cancer drugs qualifying for US food and drug administration accelerated approval. JAMA Internal Medicine, 181(4), 490 - 498. https://doi.org/10.1001/jamainternmed.2020.8441 picture_as_pdf
  • Petersen, Steffen E., Friebel, Rocco, Ferrari, Victor, Han, Yuchi, Aung, Nay, Kenawy, Asmaa, Albert, Timothy S.E., Naci, Huseyin (2021). Recent trends and potential drivers of non-invasive cardiovascular imaging use in the United States of America and England. Frontiers in Cardiovascular Medicine, 7, https://doi.org/10.3389/fcvm.2020.617771 picture_as_pdf
  • Salcher-Konrad, Maximilian, Naci, Huseyin, Davis, Courtney (2020). Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. Milbank Quarterly, 98(4), 1219 - 1256. https://doi.org/10.1111/1468-0009.12476 picture_as_pdf
  • Angelis, Aris, Naci, Huseyin, Hackshaw, Allan (2020). Recalibrating health technology assessment methods for cell and gene therapies. PharmacoEconomics, 38(12), 1297-1308. https://doi.org/10.1007/s40273-020-00956-w picture_as_pdf
  • Naci, Huseyin, Kesselheim, Aaron S., Rttingen, John Arne, Salanti, Georgia, Vandvik, Per O., Cipriani, Andrea (2020). Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. The BMJ, 371, https://doi.org/10.1136/bmj.m3869 description
  • Salcher-Konrad, Maximilian, Naci, Huseyin (2020). Unintended consequences of coverage laws targeting cancer drugs. Journal of Law, Medicine and Ethics, 48(3), 552-554. https://doi.org/10.1177/1073110520958880 picture_as_pdf
  • Vreman, Rick A., Naci, Huseyin, Goettsch, Wim G., Mantel-Teeuwisse, Aukje K., Schneeweiss, Sebastian G., Leufkens, Hubert G.M., Kesselheim, Aaron S. (2020). Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 108(2), 350-357. https://doi.org/10.1002/cpt.1835 picture_as_pdf
  • Naci, Huseyin, Kesselheim, Aaron S. (2020). Specialty drugs: a distinctly American phenomenon. New England Journal of Medicine, 382(23), 2179 - 2181. https://doi.org/10.1056/NEJMp1909513 picture_as_pdf
  • Singh, Ilina, Naci, Huseyin, Miller, Jennifer, Caplan, Arthur, Cipriani, Andrea (2020). Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. The Lancet, 395(10228), 926 - 928. https://doi.org/10.1016/S0140-6736(20)30413-X picture_as_pdf
  • Cipriani, Andrea, Ioannidis, John P.A., Rothwell, Peter M., Glasziou, Paul, Li, Tianjing, Hernandez, Adrian F., Tomlinson, Anneka, Simes, John, Naci, Huseyin (2020). Generating comparative evidence on new drugs and devices after approval. The Lancet, 395(10228), 998-1010. https://doi.org/10.1016/S0140-6736(19)33177-0 picture_as_pdf
  • Naci, Huseyin, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Dr.rer.nat, Beate Wiesler, Rochaix, Lise, Redberg, Rita, Salanti, Georgia, Jackson, Emily, Garner, Sarah & Stroup, Scott et al (2020). Generating comparative evidence on new drugs and devices before approval. The Lancet, 395(10228), 986 - 997. https://doi.org/10.1016/S0140-6736(19)33178-2 picture_as_pdf
  • Pinto, Ashlyn, Naci, Huseyin, Neez, Emilie, Mossialos, Elias (2020). Association between the use of surrogate measures in pivotal trials and health technology assessment decisions: a retrospective analysis of NICE and CADTH reviews of cancer drugs. Value in Health, 23(3), 319-327. https://doi.org/10.1016/j.jval.2019.10.010 picture_as_pdf
  • Aung, Nay, Doimo, Sara, Ricci, Fabrizio, Sanghvi, Mihir M., Pedrosa, Cesar, Woodbridge, Simon P., Al-Balah, Amer, Zemrak, Filip, Khanji, Mohammed Y. & Munroe, Patricia B. et al (2020). Prognostic significance of left ventricular noncompaction: systematic review and meta-analysis of observational studies. Circulation: Cardiovascular Imaging, 13(1). https://doi.org/10.1161/CIRCIMAGING.119.009712 picture_as_pdf
  • Athanasiou, Antonios, Veroniki, Areti Angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Naci, Huseyin, Bowden, Sarah, Paraskevaidi, Maria, Martin-Hirsch, Pierre, Bennett, Philip & Paraskevaidis, Evangelos et al (2019). Comparative fertility and pregnancy outcomes after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE group. BMJ Open, 9(10). https://doi.org/10.1136/bmjopen-2018-028009 picture_as_pdf
  • Neez, Emilie Marie Celine Anne, Hwang, Thomas, Sahoo, Samali Anova, Naci, Huseyin (2019). European Medicines Agency’s Priority Medicines scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. Clinical Pharmacology and Therapeutics, 107(3), 541-552. https://doi.org/10.1002/cpt.1669 picture_as_pdf
  • Naci, Huseyin, Davis, Courtney, Savović, Jelena, Higgins, Julian P. T., Sterne, Jonathan, Gyawali, Bishal, Romo Sandoval, Xochitl Citlalli, Handley, Nicola, Booth, Christopher M (2019). Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross-sectional analysis. BMJ, 366(8214). https://doi.org/10.1136/bmj.l5221 picture_as_pdf
  • Athanasiou, Antonios, Veroniki, Areti Angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Naci, Huseyin, Bowden, Sarah, Paraskevaidi, Maria, Martin-Hirsch, Pierre, Bennett, Philip & Paraskevaidis, Evangelos et al (2019). Comparative efficacy and complication rates after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group. BMJ Open, 9(8). https://doi.org/10.1136/bmjopen-2018-028008 picture_as_pdf
  • Salcher-Konrad, Maximilian, Naci, Huseyin, McDaid, David, Alladi, Suvarna, Oliveira, Déborah, Fry, Andra, Hussein, Shereen, Knapp, Martin, Comas-Herrera, Adelina & Musyimi, Christine et al (2019). Effectiveness of interventions for dementia in low- and middle-income countries: protocol for a systematic review, pairwise and network meta-analysis. BMJ Open, 9(6). https://doi.org/10.1136/bmjopen-2018-027851 picture_as_pdf
  • Hocaoglu, M. B., Gurkas, S., Karaderi, T., Taneri, B., Erguler, K., Barin, B., Bilgin, E. M., Eralp, G., Allison, M. & Findikli, N. et al (2019). Cyprus women's health research (COHERE) initiative: determining the relative burden of women's health conditions and related co-morbidities in an Eastern Mediterranean population. BMC Women's Health, 19(1). https://doi.org/10.1186/s12905-019-0750-1 picture_as_pdf
  • Hopkin, Gareth, Au, Anson, Collier, Verena Jane, Yudkin, John S, Basu, Sanjay, Naci, Huseyin (2019). Combining multiple treatment comparisons with personalized patient preferences: a randomized trial of an interactive platform for statin treatment selection. Medical Decision Making, 39(3), 264-277. https://doi.org/10.1177/0272989X19835239 picture_as_pdf
  • Choi, Sung Eun, Berkowitz, Seth A., Yudkin, John S., Naci, Huseyin, Basu, Sanjay (2019). Personalizing second-line Type 2 diabetes treatment selection: combining network meta-analysis, individualized risk, and patient preferences for unified decision support. Medical Decision Making, 39(3), 239-252. https://doi.org/10.1177/0272989X19829735
  • Naci, Huseyin, Salcher-Konrad, Maximilian, Mcguire, Alistair, Berger, Felix, Kuehne, Titus, Goubergrits, Leonid, Muthurangu, Vivek, Wilson, Ben, Kelm, Marcus (2019). Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. npj Digital Medicine, 2(1). https://doi.org/10.1038/s41746-019-0085-1 picture_as_pdf
  • Naci, Huseyin, Dixon, Jennifer (2019). New agreement on branded drugs for the NHS. BMJ (Online), 364, p. 1266. https://doi.org/10.1136/bmj.l266
  • Naci, Huseyin, Salcher-Konrad, Maximilian, Dias, Sofia, Blum, Manuel R., Sahoo, Samali Anova, Nunan, David, Ioannidis, John P. A. (2018). How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 RCTs assessing exercise and medication effects on systolic blood pressure. British Journal of Sports Medicine, https://doi.org/10.1136/bjsports-2018-099921 picture_as_pdf
  • Crispi, Francisca, Naci, Huseyin, Barkauskaite, Eva, Osipenko, Leeza, Mossialos, Elias (2018). Assessment of devices, diagnostics and digital technologies: a review of NICE medical technologies guidance. Applied Health Economics and Health Policy, https://doi.org/10.1007/s40258-018-0438-y picture_as_pdf
  • Anderson, Michael, Naci, Huseyin, Morrison, Deborah, Osipenko, Leeza, Mossialos, Elias (2018). A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. Journal of Clinical Epidemiology, https://doi.org/10.1016/j.jclinepi.2018.09.003
  • Salanti, Georgia, Nikolakopoulou, Adriani, Sutton, Alex J., Reichenbach, Stephan, Trelle, Sven, Naci, Huseyin, Egger, Matthias (2018). Planning a future randomized clinical trial based on a network of relevant past trials. Trials, 19(365). https://doi.org/10.1186/s13063-018-2740-2
  • Wallach, Joshua D., Ross, Joseph S., Naci, Huseyin (2018). The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. Clinical Trials, https://doi.org/10.1177/1740774518770648
  • Wallach, Joshua D., Ross, Joseph S., Naci, Huseyin (2018). The US Food and Drug Administration’s expedited approval programs: addressing premarket flexibility with enhanced postmarket evidence generation. Clinical Trials, 15(3), 243-246. https://doi.org/10.1177/1740774518770657
  • Naci, Huseyin, Vardas, Panos, Vahanian, Alec, Kirchhof, Paulus, Bardinet, Isabel, Mossialos, Elias (2017). Training the next generation of cardiovascular leaders in health policy and economics. European Heart Journal, 38(45), 3332-3335. https://doi.org/10.1093/eurheartj/ehx673
  • Naci, Huseyin, Mossialos, Elias (2017). Accelerated access to new drugs and technologies. BMJ, 359, 1-2. https://doi.org/10.1136/bmj.j5387
  • Naci, Huseyin (2017). What to do (or not to do) when randomization is not possible. Journal of Heart and Lung Transplantation, 36(11), 1174-1177. https://doi.org/10.1016/j.healun.2017.07.008
  • Davis, Courtney, Naci, Huseyin, Gurpinar, Evrim, Poplavska, Elita, Pinto, Ashlyn, Aggarwal, Ajay (2017). Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ, 359(359). https://doi.org/10.1136/bmj.j4530
  • Wenzl, Martin, Naci, Huseyin, Mossialos, Elias (2017). Health policy in times of austerity — a conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008. Health Policy, 121(9), 947-954. https://doi.org/10.1016/j.healthpol.2017.07.005
  • Naci, Huseyin, Smalley, Katelyn R., Kesselheim, Aaron S. (2017). Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration. JAMA, 318(7), 626-636. https://doi.org/10.1001/jama.2017.9415
  • Naci, Huseyin, Wouters, Olivier J., Gupta, Radhika, Ioannidis, John P. A. (2017). Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. The Milbank Quarterly, 95(2), 261 - 290. https://doi.org/10.1111/1468-0009.12261
  • Kaier, K., Reinecke, H., Naci, Huseyin, Frankenstein, L., Bode, M., Vach, W., Hehn, P., Zirlik, A., Zehender, M., Reinöhl, J. (2017). The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany. European Journal of Health Economics, 19(2), 223-228. https://doi.org/10.1007/s10198-017-0877-7
  • Naci, Huseyin (2016). Communication of treatment rankings obtained from network meta-­analysis using data visualization. Circulation: Cardiovascular Quality and Outcomes, 9(5), 605-608. https://doi.org/10.1161/CIRCOUTCOMES.116.002874
  • Dhutia, Harshil, Malhotra, Aneil, Gabus, Vincent, Merghani, Ahmed, Finocchiaro, Gherardo, Millar, Lynne, Narain, Rajay, Papadakis, Michael, Naci, Huseyin & Tome, Maite et al (2016). Cost implications of using different ECG criteria for screening young athletes in the United Kingdom. Journal of the American College of Cardiology, 68(7), 702-711. https://doi.org/10.1016/j.jacc.2016.05.076
  • Naci, Huseyin, Soumerai, Stephen B. (2016). History bias, study design, and the unfulfilled promise of pay-for-performance policies in health care. Preventing Chronic Disease, 13(160133), 1-7. https://doi.org/10.5888/pcd13.160133
  • Salcher, Maximilian, Naci, Huseyin, Law, Tyler J., Kuehne, Titus, Schubert, Stephan, Kelm, Marcus (2016). Balloon dilatation and stenting for aortic coarctation: a systematic review and meta-analysis. Circulation: Cardiovascular Interventions, https://doi.org/10.1161/CIRCINTERVENTIONS.115.003153
  • Luyten, Jeroen, Naci, Huseyin, Knapp, Martin (2016). Economic evaluation of mental health interventions: an introduction to cost-utility analysis. Evidence-Based Mental Health, 19, 49-53. https://doi.org/10.1136/eb-2016-102354
  • Wouters, Olivier J., Naci, Huseyin, Samani, Nilesh J (2015). QALYs in cost-effectiveness analysis: an overview for cardiologists. Heart, 10(23), 1868-1873. https://doi.org/10.1136/heartjnl-2015-308255
  • Naci, Huseyin, Basu, Sanjay, Yudkin, John S (2015). Preventing cardiovascular events with empagliflozin: at what cost? The Lancet Diabetes and Endocrinology, 3(12), p. 931. https://doi.org/10.1016/S2213-8587(15)00439-8
  • Naci, Huseyin, Carter, Alexander W., Mossialos, Elias (2015). Why the drug development pipeline is not delivering better medicines. BMJ, 351, https://doi.org/10.1136/bmj.h5542
  • Tervonen, Tommi, Naci, Huseyin, van Valkenhoef, Gert, Ades, Anthony E., Angelis, Aris, Hillege, Hans L., Postmus, Douwe (2015). Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention. Medical Decision Making, 35(7), 859-871. https://doi.org/10.1177/0272989X15587005
  • Naci, Huseyin, Carter, Alexander W., Mossialos, Elias (2015). Double failure: the shared accountability of governments and firms for the innovation deficit in the pharmaceutical sector. BMJ, picture_as_pdf
  • Naci, Huseyin, Ioannidis, John P. A. (2015). Evaluation of wellness determinants and interventions by citizen scientists. JAMA, 314(2), p. 121.
  • Mossialos, Elias, Courtin, Emilie, Naci, Huseyin, Benrimoj, Shalom, Bouvy, Marcel, Farris, Karen, Noyce, Peter, Sketris, Ingrid (2015). From "retailers" to health care providers: transforming the role of community pharmacists in chronic disease management. Health Policy, 119(5), 628-639. https://doi.org/10.1016/j.healthpol.2015.02.007 picture_as_pdf
  • Naci, Huseyin, Ioannidis, John P. A. (2015). How good is "Evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of clinical utility of drugs. Annual Review of Pharmacology and Toxicology, 55, 169-189. https://doi.org/10.1146/annurev-pharmtox-010814-124614
  • Jackson, N., Atar, D., Borentain, M., Breithardt, G., van Eickels, M., Endres, M., Fraass, U., Friede, T., Hannachi, H. & Janmohamed, S. et al (2015). Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, https://doi.org/10.1093/eurheartj/ehv213
  • Naci, Huseyin, Lehman, Richard, Wouters, Olivier J., Goldacre, Ben, Yudkin, John S (2015). Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ, 351(h5260). https://doi.org/10.1136/bmj.h5260
  • Naci, Huseyin, Cooper, Jacob, Mossialos, Elias (2015). Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease. European Heart Journal - Quality of Care and Clinical Outcomes, https://doi.org/10.1093/ehjqcco/qcv012
  • Chambers, James D., Naci, Huseyin, Wouters, Olivier J., Pyo, Junhee, Gunjal, Shalak, Kennedy, Ian R., Hoey, Mark G., Winn, Aaron, Neumann, Peter J. (2015). An assessment of the methodological quality of published network meta-analyses: a systematic review. PLOS ONE, 10(4). https://doi.org/10.1371/journal.pone.0121715
  • Naci, Huseyin, Dias, Sofia, Ades, A. E. (2014). Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ, 349(oct03), g5741-g5741. https://doi.org/10.1136/bmj.g5741
  • Naci, Huseyin, Alexander, George Caleb (2014). Regulators should better leverage effectiveness standards to enhance drug value. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 34(10), 1005-1011. https://doi.org/10.1002/phar.1467
  • Naci, Huseyin, van Valkenhoef, G., Higgins, J. P. T., Fleurence, R., Ades, A. E. (2014). Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs. Circulation: Cardiovascular Quality and Outcomes, 7(5), 787-792. https://doi.org/10.1161/CIRCOUTCOMES.114.000825
  • Naci, Huseyin, Soumerai, Stephen B, Ross-Degnan, Dennis, Zhang, Fang, Briesacher, Becky A., Gurwitz, Jerry H., Madden, Jeanne M. (2014). Medication affordability gains following Medicare Part D are eroding among elderly with multiple chronic conditions. Health Affairs, 33(8), 1435-1443. https://doi.org/10.1377/hlthaff.2013.1067 picture_as_pdf
  • Naci, Huseyin (2014). Persistent medication affordability problems among disabled medicare beneficiaries after Part D, 2006-2011. Medical Care, 52(11), 951-956. https://doi.org/10.1097/MLR.0000000000000205
  • Naci, Huseyin, O’Connor, Alec B (2013). Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. Journal of Clinical Epidemiology, 66(8), 812-816. https://doi.org/10.1016/j.jclinepi.2013.04.002
  • Naci, H., Brugts, J. J., Fleurence, R., Tsoi, B., Toor, H., Ades, A. E. (2013). Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: A network meta-analysis of placebo-controlled and active-comparator trials. European Journal of Preventive Cardiology, 20(4), 641-657. https://doi.org/10.1177/2047487313480435
  • Naci, Huseyin, Brugts, Jasper Jan, Fleurence, Rachael, Ades, Anthony E. (2013). Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. European Journal of Preventive Cardiology, 20(4), 658-670. https://doi.org/10.1177/2047487313483600
  • Naci, Huseyin, Brugts, Jasper Jan, Ades, Tony (2013). Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circulation: Cardiovascular Quality and Outcomes, 6(4), 390-399. https://doi.org/10.1161/CIRCOUTCOMES.111.000071
  • Jansen, Jeroen P., Naci, Huseyin (2013). Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Medicine, 11(1), p. 159. https://doi.org/10.1186/1741-7015-11-159
  • Mossialos, Elias, Naci, Huseyin, Courtin, Emilie (2013). Expanding the role of community pharmacists: policymaking in the absence of policy-relevant evidence? Health Policy, 111(2), 135-148. https://doi.org/10.1016/j.healthpol.2013.04.003
  • Naci, Huseyin, Brugts, Jasper Jan, Fleurence, Rachael, Ades, Anthony E. (2013). Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials. QJM - Monthly Journal of the Association of Physicians, 106(4), 299-306. https://doi.org/10.1093/qjmed/hct041
  • Naci, H., Ioannidis, J. P. A. (2013). Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. The BMJ, 347(oct01), 1-14. https://doi.org/10.1136/bmj.f5577
  • Rahmioglu, Nilufer, Naci, Huseyin, Cylus, Jonathan (2012). Improving health care services in Northern Cyprus: a call for research and action. European Journal of Public Health, 22(6), 754-755. https://doi.org/10.1093/eurpub/cks145
  • Winter, H.S., Mossialos, E., Naci, Huseyin, Chandra, A., Salojee, H., Yamashiro, Y., Bhutta, Z.A., Uauy, R., Corvalan, C. (2012). The economics of health care delivery. Journal of Pediatric Gastroenterology and Nutrition, 55(5), 482-488. https://doi.org/10.1097/MPG.0b013e318272af3b
  • Naci, Huseyin, Cylus, Jonathan, Vandoros, Sotiris, Sato, Azusa, Perampaladas, Kumar (2012). Raising the bar for market authorisation of new drugs. The BMJ, 345, e4261-e4261. https://doi.org/10.1136/bmj.e4261
  • Naci, Huseyin, de Lissovoy, Gregory, Hollenbeak, Christopher, Custer, Brian, Hofmann, Axel, McClellan, William, Gitlin, Matthew (2012). Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. Journal of Medical Economics, 15(2), 293-304. https://doi.org/10.3111/13696998.2011.644407
  • Chisholm, Daniel, Naci, Huseyin, Hyder, Adnan Ali, Tran, Nhan T., Peden, Margie (2012). Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ, 344(mar02), e612-e612. https://doi.org/10.1136/bmj.e612
  • Naci, Huseyin, Fleurence, Rachael (2011). Using indirect evidence to determine the comparative effectiveness of prescription drugs: do benefits outweigh risks? Health Outcomes Research in Medicine, 2(4), e241-e249.
  • Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan, Mossialos, Elias (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343(7822), d4849-d4849. https://doi.org/10.1136/bmj.d4849
  • Naci, Huseyin (2011). The increasing need to harmonize evidence demands of regulators, payers, and health technology assessment bodies in Europe – opportunities and challenges. ISPOR Connections, 17(4), 4-6.
  • Fleurence, Rachel L., Naci, Huseyin, Jansen, Jeroen P. (2010). The critical role of observational evidence in comparative effectiveness research. Health Affairs, 29(10), 1826-1833. https://doi.org/10.1377/hlthaff.2010.0630
  • McIntyre, Roger S., Cragin, Lael, Sorensen, Sonja, Naci, Huseyin, Baker, Tim, Roussy, Jean-Pascal (2010). Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. Journal of Evaluation in Clinical Practice, 16(4), 744-755. https://doi.org/10.1111/j.1365-2753.2009.01189.x
  • Naci, Huseyin, Fleurence, Rachael, Birt, Julie, Duhig, Amy (2010). Economic burden of multiple sclerosis. PharmacoEconomics, 28(5), 363-379. https://doi.org/10.2165/11532230-000000000-00000
  • Naci, Huseyin, Fleurence, Rachael, Birt, Julie, Duhig, Amy (2010). The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. Journal of Medical Economics, 13(1), 78-89. https://doi.org/10.3111/13696990903543085
  • Naci, H., Chisholm, D., Baker, T. D. (2009). Distribution of road traffic deaths by road user group: a global comparison. Injury Prevention, 15(1), 55-59. https://doi.org/10.1136/ip.2008.018721
  • Naci, Huseyin, Baker, Timothy D. (2008). Productivity losses from road traffic deaths in Turkey. International Journal of Injury Control and Safety Promotion, 15(1), 19-24. https://doi.org/10.1080/17457300701847648
  • Naci, Huseyin, Leontsini, Elli, Baker, Timothy D. (2007). One island, two parts, shared aspirations. Harvard Health Policy Review, Fall(2), 108-110.
    • Chapter
  • Naci, Huseyin, Spackman, Eldon, Fleurence, Rachael (2015). National approaches to comparative effectiveness research. In Sobolev, B. (Ed.), Handbook of Health Services Research . Springer Berlin / Heidelberg.
    • Dataset
  • Salcher-Konrad, Maximilian, Nguyen, Mary, Naci, Huseyin (2024). Dataset: effect estimates obtained from randomised and non-randomised studies. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.4958221
    • Report
  • Knapp, Martin, Silva Ribeiro, Wagner, Naci, Huseyin, McDaid, David, Walbaum, Magdalena, Wong, Gloria, King, Derek, Anderson, Jodie, Bostock, Jennifer & Cyhlarova, Eva et al (2025). UKRI R&D missions accelerator programme NHS fit for the future: exploring the potential for greatest gains. London School of Economics and Political Science. Care Policy and Evaluation Centre. picture_as_pdf
    • Thesis
  • Naci, Huseyin (2014). Generating comparative data on clinical benefits and harms of statins to inform prescribing decisions: evidence from network meta-analyses [Doctoral thesis]. London School of Economics and Political Science.
    • Online resource
  • Olczak, Kaya, Salcher, Maximillian, Naci, Huseyin (2016). What works best in congenital heart disease? Comparing two interventions for treatment of Aortic Coarctation.
  • Naci, Huseyin (2014). Does industry sponsorship bias research findings?
  • Naci, Huseyin, Cylus, Jonathan (2012). Why a stricter regulation of drugs could foster (not deter) pharmaceutical innovation.
    • Working paper
  • Chisholm, Dan, Naci, Huseyin (2008). Road traffic injury prevention: an assessment of risk exposure and intervention cost-effectiveness in different world regions. (HSF discussion papers). World Health Organization.
    • Blog post
  • Naci, Huseyin, Woods, Beth, Lomas, James, Wei, Jinru (13 December 2024) Why pharmaceutical pricing needs reform. British Politics and Policy at LSE. picture_as_pdf